Skip to main content

Our ongoing studies have successfully developed a novel mouse model of thrombolysis (iCAT) that for the first time allows us the ability to examine the efficacy of novel drugs including novel thrombin inhibitors to facilitate clot lysis (recanalization), restore perfusion in the brain, as well as determine whether cerebral damage and cognitive impairment associated with stroke are reduced. We are using this model to assess the efficacy of currently approved and novel anticlotting agents to facilitate stroke treatment.

HRI breakthrough drug for coronavirus

Read full article